LONDON–(BUSINESS WIRE)–Dec 2, 2020–
Gyroscope Therapeutics Restricted, a clinical-stage retinal gene remedy firm, at present introduced that Jennifer Cook dinner, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Administrators, efficient instantly.
“I’m very happy to welcome Jennifer, David, and Renée, three extraordinarily completed executives with in depth biopharmaceutical backgrounds, to our board of administrators,” mentioned Khurem Farooq, Chief Govt Officer. “We look ahead to their useful contributions and distinctive views as we proceed our work to develop gene remedy past uncommon illness with the purpose of delivering new medicines to individuals with retinal illnesses.”
Ms. Cook dinner was most just lately the Chief Govt Officer of GRAIL, a healthcare firm centered on the early detection of most cancers. Previous to becoming a member of GRAIL, she held a variety of management positions throughout her 25-year tenure with Roche/Genentech, together with main Roche Prescribed drugs’ European industrial enterprise, World Medical Operations, U.S. and World Product Portfolio Administration, the U.S. Immunology and Ophthalmology Enterprise Unit and Market Growth. She presently serves on the boards of administrators of Denali Therapeutics, BridgeBio Pharma and Ambys Medicines. Ms. Cook dinner holds a B.A. in human biology and an M.S. in biology from Stanford College, in addition to an MBA from the Haas College of Enterprise on the College of California, Berkeley.
Mr. Fellows was most just lately the Chief Govt Officer of Nightstar Therapeutics, a retinal gene remedy firm acquired by Biogen in 2019. Previous to becoming a member of Nightstar, he was the Vice President of Johnson & Johnson’s Imaginative and prescient Care Franchise the place he led the worldwide advertising, new product and licensing actions. Earlier than becoming a member of Johnson & Johnson, Mr. Fellows held management positions at Allergan, Inc., for 25 years the place he served primarily in gross sales and advertising in a variety of capacities, together with Regional President, Company Vice President, and Senior Vice President throughout North America, Europe and Asia. He presently serves because the chairman of the board for Oxular Restricted and is a board member of the Glaucoma Basis. Mr. Fellows holds a B.A. in psychology from Butler College.
Ms. Galá presently serves because the Govt Vice President and Chief Monetary Officer of Jazz Prescribed drugs, a world biopharmaceutical firm. Previous to becoming a member of Jazz, she served because the Chief Monetary Officer of GRAIL. Earlier than becoming a member of GRAIL, Ms. Galá served because the Senior Vice President and Chief Monetary Officer of Theravance Biopharma, the place she led the corporate’s spin-out transaction from Innoviva, Inc. Ms. Galá has additionally served in world treasury, pharmaceutical gross sales and company technique/enterprise improvement at Eli Lilly and Firm. Previous to becoming a member of Eli Lilly, she spent seven years within the power business in positions centered on company finance, mission finance and mergers and acquisitions. She presently serves on the board of administrators of Gossamer Bio the place she chairs its audit committee. Ms. Galá holds a B.S. in arithmetic from Vanderbilt College and an MBA from Columbia Enterprise College.
About Gyroscope: Imaginative and prescient for Life
Gyroscope Therapeutics is a clinical-stage retinal gene remedy firm growing gene remedy past uncommon illness to deal with a number one reason behind blindness, dry age-related macular degeneration (AMD). Our lead investigational gene remedy, GT005, is a one-time remedy delivered underneath the retina. GT005 is designed to revive steadiness to an overactive complement system by growing manufacturing of the Complement Issue I protein. GT005 is presently being evaluated in a Section I/II scientific trial referred to as FOCUS and Section II scientific trials referred to as EXPLORE and HORIZON.
Syncona Ltd, our lead investor, helped us create a number one retinal gene remedy firm combining discovery, analysis, drug improvement, a producing platform and surgical supply capabilities. Headquartered in London with places in Philadelphia and San Francisco, our mission is to protect sight and struggle the devastating impression of blindness. For extra data go to: www.gyroscopetx.com and observe us on Twitter ( @GyroscopeTx ) and on LinkedIn.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20201201006277/en/
CONTACT: Charlotte Arnold
VP, Company Affairs
KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL OPTICAL CLINICAL TRIALS
SOURCE: Gyroscope Therapeutics Restricted
Copyright Enterprise Wire 2020.
PUB: 12/02/2020 01:00 AM/DISC: 12/02/2020 01:01 AM
Copyright Enterprise Wire 2020.